Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Patients with interstitial lung disease associated with systemic sclerosis were treated with usual care plus placebo or nintedanib. The annual rate of change in forced vital capacity assessed over a 52-week period was −52.4 ml per year with nintedanib and −93.3 ml per year with placebo. There were n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-06, Vol.380 (26), p.2518-2528
Hauptverfasser:	Distler, Oliver, Highland, Kristin B, Gahlemann, Martina, Azuma, Arata, Fischer, Aryeh, Mayes, Maureen D, Raghu, Ganesh, Sauter, Wiebke, Girard, Mannaig, Alves, Margarida, Clerisme-Beaty, Emmanuelle, Stowasser, Susanne, Tetzlaff, Kay, Kuwana, Masataka, Maher, Toby M
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Clinical trials Computed tomography Diarrhea Diarrhea - chemically induced Disease Progression Double-Blind Method Double-blind studies Enzyme inhibitors Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Female Fibrosis Humans Indoles - adverse effects Indoles - therapeutic use Lung diseases Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Lung Diseases, Interstitial - physiopathology Male Middle Aged Mycophenolic acid Oral administration Patients Protein-tyrosine kinase Protein-Tyrosine Kinases - antagonists & inhibitors Pulmonary fibrosis Pulmonary hypertension Rheumatology Scleroderma Scleroderma, Systemic - complications Scleroderma, Systemic - drug therapy Sensitivity analysis Skin Systemic sclerosis Technical communication Vital Capacity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with interstitial lung disease associated with systemic sclerosis were treated with usual care plus placebo or nintedanib. The annual rate of change in forced vital capacity assessed over a 52-week period was −52.4 ml per year with nintedanib and −93.3 ml per year with placebo. There were no differences in other measures of systemic sclerosis.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1903076